Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
05:26am, Saturday, 04'th May 2024
Eli Lilly stock is way up over the past year, but analysts who follow the company think it still has more upside. Sales of Eli Lilly's weight-management treatment are soaring and could climb much high
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?
07:23pm, Thursday, 02'nd May 2024
The pharmaceutical sector mainstay has attracted much attention with a recently approved drug. It also posted impressive quarterly results at the end of April.
Earnings Season: 3 Companies Boosting Guidance
04:01pm, Thursday, 02'nd May 2024
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks followin
Here's Why Eli Lilly Stock Remains a Screaming Buy
05:45am, Thursday, 02'nd May 2024
Lilly's Mounjaro and Zepbound should have tremendous growth ahead. The company could have even better weight loss drugs in its pipeline.
Is this semiconductor stock the next trillion-dollar company? Why it's worth adding to your portfolio now
05:36am, Thursday, 02'nd May 2024
Many have come to believe that artificial intelligence is the next stepping stone to propel the global economy to new heights. However, the giant on whose shoulder stands the development of AI is the
3 stocks poised for trillion-dollar valuations to consider today
05:36am, Thursday, 02'nd May 2024
Identifying the next trillion-dollar market is a serious challenge. Reaching a trillion-dollar market cap symbolizes more than just financial success; it reflects a company's profound global impact, e
Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers)
03:36pm, Wednesday, 01'st May 2024
We're a little more than halfway through first-quarter earnings season, so now is the time to review this earnings season winners and losers. In general, market results have been encouraging so far.
Trade Tracker: Joe Terranova sells Eli Lilly
01:49pm, Wednesday, 01'st May 2024
The Investment Committee discusses the healthcare sector as Joe Terranova sells Eli Lilly in his JOET rebalance.
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
12:01pm, Wednesday, 01'st May 2024
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
11:59am, Wednesday, 01'st May 2024
While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of reces
Nearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks
10:00am, Wednesday, 01'st May 2024
Stanley Druckenmiller has one of the best investing records out there. He worked closely with George Soros, helping to "break the Bank of England.
These 3 Companies Recently Lifted Guidance
06:56pm, Tuesday, 30'th Apr 2024
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs
01:30pm, Tuesday, 30'th Apr 2024
Shares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its offerings. BMO Capital Markets BioPharma Equity
Eli Lilly and Company (LLY) Q1 2024 Earnings Call Transcript
01:27pm, Tuesday, 30'th Apr 2024
Eli Lilly and Company (NYSE:LLY ) Q1 2024 Earnings Conference Call April 30, 2024 10:00 AM ET Company Participants Joe Fletcher – Senior Vice President-Investor Relations Dave Ricks – Chief Execut
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
12:46pm, Tuesday, 30'th Apr 2024
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
